The approval was based on data from the phase 3 KEYNOTE-826 trial.
Your search for bevacizumab returned 2 results
Tisotumab vedotin is an investigational antibody-drug conjugate targeted to tissue factor.
The approval was based on data from the phase 3 KEYNOTE-826 trial.
Tisotumab vedotin is an investigational antibody-drug conjugate targeted to tissue factor.